HER2-Positive Breast Cancer: Current Treatment Strategies

s of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2005 [abstr 2]. 27. Burstein, H.J.; Harris, L.N. ; German, R. ; Lester, S.C. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003, 21(1), 46–53. 28. Harris, L.N. ; Burstein, H.J.; German, R. ; et al. Preoperative trastuzumab and vinorelbine is highly active, well-tolerated regimen for HER2 3+/FISH + stage II/III breast cancer [abstr 86]. Proc Am Soc Clin Oncol 2003, 22 (abstract no. 86). 29. Hurley, J.; Dolina, P.; Silva, O. ; et al. Neoadjuvant herceptin/taxotere/cisplatin in the treat ment of locally advanced and HER2-Positive Breast Cancer 551 inflammatory breast cancer [abstr 196]. Proc Am Soc Clin Oncol 2002, 21 (abstract no. 196). 30. Van Pelt, A.F. ; Mohsin, S. ; Elledge, R.M. ; et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 2003, 4, 348–353. 31. Limentani, S.A. ; Brufsky, A.M.; Erban, J.K. ; et al. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Breast Cancer Res Treat 2003, 82, S55. 32. Carey, L.A. ; Dees, E.C. ; Sawyer, L. ; et al. Response to trastuzumab given with paclitaxel immediately following 4AC as initial therapy for primary breast cancer. Proceedings of the 24th San Antonio Breast Cancer Symposium, 2002. 33. Buzdar, A.U. ; Ibrahim, N.K. ; Francis, D. ; et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2positive operable breast cancer. J Clin Oncol 2005, 23(16), 3676– 3685. 34. Seidman, A. ; Hudis, C. ; Pierri, M.K. ; et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20(5), 1215–1221. 35. “The Pink Sheet” FDC Reports. Chevy Chase, MD, 2001, 63(29), 12. 36. Tripathy, D. ; Seidman, A. ; Keefe, D. ; et al. Effect of cardiac dysfunction on treatment out comes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2004, 5(4), 293–298. 37. Perez, E.A. ; Suman, V.J.; Davidson, N.E. ; et al. Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Program and abstracts of the 28th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2005 [abstr 2038]. 38. Bianco, A.R. ; De Laurentiis, M. ; Carlomagno, C. ; et al. 20 years update of the Naples GUN Trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy [abstr]. Proc Am Soc Clin Oncol 1998, 17, 97a. 39. Ellis, M.J.; Coop, A. ; Singh, B. ; et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19, 3808. 40. Pritchard, K.I. ; Levine, M.N. ; Tu, D. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? Part II. J Clin Oncol 2003, 21, 399. 41. Bast, R.C. ; Jr. Ravdin, P.; Hayes, D.P.; et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19, 1865. 42. Allred, D.C.; Clark, G. ; Tandon, A. ; et al. HER-2/neu in nodenegative breast cancer: prog nostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10, 599. 43. Paik, S. ; Bryant, J.; Park, C. ; et al. erbB-2 and response to doxorubicin in patients with axil lary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90, 1361. 44. Jarvinen, T.A. ; Tanner, M. ; Rantanen, V. ; et al. Amplification and deletion of topoisomerase I alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000, 156(3), 839–847. 45. Knoop, A.S. ; Knudsen, H. ; Balslev, E. ; et al. Retrospective analysis of topoisomerase Ila amplifications and deletions as predictive markers in primary breast cancer patients ran domly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005, 23(30), 7483–7490. 46. Sjostrom, J.; Collan, J.; von Boguslawski, K. ; et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002, 38, 535. 552 E. A. Perez and M. Baweja